文献速递乳腺癌

靶向Ropporin-1的TCR工程化T细胞构成三阴性乳腺癌的安全有效治疗

TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer.
PubMed 文献 · Cancer Discov · 2024-01-01

研究将Ropporin-1(ROPN1)鉴定为三阴性乳腺癌(TNBC)的T细胞治疗靶点,ROPN1在90%的原发性和转移性TNBC中高表达且均一,而在健康组织中不表达。研究者从初始T细胞库中筛选出针对表位FLYTYIAKV的高特异性T细胞受体(TCR),该TCR在体外三维肿瘤球和体内肿瘤细胞中展现出杀伤作用,并优于标准治疗药物。表达该TCR的T细胞产品按临床方案生产,符合标准安全性和有效性检测,临床前验证支持抗ROPN1 TCR T细胞用于绝大多数TNBC患者。

要点

  • ROPN1在90%的原发性和转移性TNBC中高表达且均一,健康组织不表达。
  • 筛选出的抗ROPN1 TCR高特异性识别表位FLYTYIAKV,不识别其他来源蛋白的非 cognate 表位。
  • 该TCR介导的杀伤在体外3D肿瘤球和体内肿瘤细胞中优于标准治疗药物。

核心结论

  • ROPN1被鉴定并临床前验证为TNBC靶点,抗ROPN1 TCR T细胞可作为绝大多数TNBC患者的治疗。

研究设计与样本

  • 临床前研究:通过免疫肽组学和预测鉴定HLA-A2结合肽,从初始T细胞库中获取TCR,经基因导入T细胞并严格筛选获得高特异性TCR。

主要发现

  • ROPN1在90%的原发性和转移性TNBC中高表达且均一,健康组织不表达。
  • 筛选出的TCR针对表位FLYTYIAKV,不识别其他来源蛋白的非 cognate 表位。
  • 该TCR介导的杀伤在体外3D肿瘤球和体内肿瘤细胞中均有效,并优于标准治疗药物。
  • 表达该TCR的T细胞产品按临床方案生产,符合标准安全性和有效性检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Triple-negative breast cancer (TNBC) has an urgent need for new therapies. We discovered Ropporin-1 (ROPN1) as a target to treat TNBC with T cells. ROPN1 showed high and homogenous expression in 90% of primary and metastatic TNBC but not in healthy tissues. Human leukocyte antigen-A2-binding peptides were detected via immunopeptidomics and predictions and used to retrieve T-cell receptors (TCR) from naïve repertoires. Following gene introduction into T cells and stringent selection, we retrieved a highly specific TCR directed against the epitope FLYTYIAKV that did not recognize noncognate epitopes from alternative source proteins. Notably, this TCR-mediated killing of three-dimensional (3D) tumoroids in vitro and tumor cells in vivo and outperformed standard-of-care drugs. Finally, the T-cell product expressing this TCR and manufactured using a clinical protocol fulfilled standard safety and efficacy assays. Collectively, we have identified and preclinically validated ROPN1 as a target and anti-ROPN1 TCR T cells as a treatment for the vast majority of patients with TNBC. Significance: Metastatic TNBC has a dismal prognosis. This study discovers Ropporin-1 as a target for T-cell therapy for most patients. The selected TCR is highly specific and sensitive in advanced models, and preclinical testing shows that the T-cell product expressing this TCR, manufactured according to good manufacturing practice, has favorable safety and potency.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Kortleve D, Hammerl D, van Brakel M, et al. TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer. Cancer Discov. 2024. PMID: 39172012. doi:10.1158/2159-8290.CD-24-0168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。